Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 28;17(2):524-527.
doi: 10.21037/jtd-24-1785. Epub 2025 Feb 25.

The APPLE's core question-upfront osimertinib versus the sequential approach for EGFR mutated non-small cell lung cancer

Joe Q Wei  1   2 , Alexander Yuile  2   3   4 , Aaron C Tan  5   6
Affiliations
Editorial

The APPLE's core question-upfront osimertinib versus the sequential approach for EGFR mutated non-small cell lung cancer

Joe Q Wei et al. J Thorac Dis. .
No abstract available

Keywords: Lung cancer; brain metastasis; circulating tumour DNA (ctDNA); tyrosine kinase inhibitor (TKI).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-1785/coif). A.C.T. reports consulting for Amgen, Bayer, Pfizer; research funding from AstraZeneca (to Institution), Takeda (to Institution); and honoraria from Amgen, AstraZeneca, Daiichi Sankyo, Guardant, Janssen, Juniper Biologics, Pfizer, Roche, Takeda; all outside the submitted work. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol 2022;40:611-25. 10.1200/JCO.21.01626 - DOI - PubMed
    1. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46. 10.1016/S1470-2045(11)70393-X - DOI - PubMed
    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed
    1. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 2020;382:41-50. 10.1056/NEJMoa1913662 - DOI - PubMed
    1. Remon J, Besse B, Aix SP, et al. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. Ann Oncol 2023;34:468-76. 10.1016/j.annonc.2023.02.012 - DOI - PubMed

LinkOut - more resources